In summary, CB1’s influence over N-type VGCC and neurotransmitter release is key to maintaining an excitatory/inhibitory balance and to preventing neural death, which suggests the possibility of evaluating cannabinoids as potential therapeutic agents in AD. The gene discussed is CNR1; the disease is Alzheimer disease.